Antibody responses to intradermal recombinant hepatitis B immunization among HIV-positive subjects.
We conducted a randomized, controlled clinical trial to determine the immunogenicity of intradermal immunization with recombinant hepatitis B vaccine among HIV-positive subjects. Induction of antibody concentration over 10 IU/L or four-fold increase in the antibody concentration against hepatitis B surface antigen was regarded a successful immunization. Intradermal immunization induced protective immunity in 39% of participants who received three doses of recombinant hepatitis B vaccine. Intradermal immunization may provide a way to improve the outcome of hepatitis B vaccination among HIV-infected persons. Three doses of intradermal immunization alone induces protective immunity against hepatitis B as often as intramuscular immunization.